



an Open Access Journal by MDPI

Chemotherapy of Leishmaniasis: Past, Present and Future

Guest Editors:

**Dr. Adriano Cappellazzo
Coelho**

Departamento de Biologia
Animal, Instituto de Biologia,
Universidade Estadual de
Campinas (UNICAMP) Rua
Monteiro Lobato 255, Campinas
13083-862, Brazil

Dr. Juliana Quero Reimão

Laboratory of Preclinical Assays
and Research of Alternative
Sources of Innovative Therapy for
Toxoplasmosis and Other
Sicknesses (PARASITTOS),
Departamento de Morfologia e
Patologia Básica, Faculdade de
Medicina de Jundiaí, Jundiaí
13202-550, Brazil

Deadline for manuscript
submissions:
closed (31 December 2024)

Message from the Guest Editors

Dear Colleagues,

Leishmaniasis is a neglected disease caused by protozoa of the genus *Leishmania*, which may manifest differently depending on the *Leishmania* species and the immune response of the human host. Only a limited number of chemotherapeutic agents are available for treating this neglected infectious disease, most of which require parenteral administration and may cause serious side effects. The search for new drugs to treat this disease is imperative.

For this Special Issue, we hope to receive original research articles and reviews that focus on current and potential new drugs for leishmaniasis chemotherapy. Additionally, this Special Issue may offer new insights into understanding the mechanisms of action and resistance of current and alternative drugs proposed for the treatment of this parasitic disease.



mdpi.com/si/188484

Special Issue